The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) with sarcomatoid and/or rhabdoid (S/R) features after progressive disease (PD) on immune checkpoint therapy (ICT): The MD Anderson Cancer Center experience.
 
Andrew Warren Hahn
No Relationships to Disclose
 
Paul Vincent Viscuse
No Relationships to Disclose
 
Devaki Shilpa Surasi
No Relationships to Disclose
 
Tharakeswara Bathala
No Relationships to Disclose
 
Andrew James Wiele
No Relationships to Disclose
 
Michael W Starbuck
No Relationships to Disclose
 
Matthew T Campbell
Honoraria - Apricity Health; Apricity Health (Inst); Aravive (Inst); Astellas Pharma; AstraZeneca (Inst); Axdev; Eisai; EMD Serono; Exelixis; Exelixis (Inst); Genentech/Roche; Janssen Oncology (Inst); Medscape; Pfizer; Pfizer (Inst); Seagen
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Exelixis; Genentech; Pfizer
Research Funding - Apricity Health (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst)
Other Relationship - Bristol-Myers Squibb; Merck; Pfizer; Roche
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Pfizer/EMD Serono
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
Eric Jonasch
Consulting or Advisory Role - aravive; Calithera Biosciences; Eisai; Exelixis; Merck; NiKang Therapeutics; Novartis; Pfizer
Research Funding - Aravive; Novartis; Peloton Therapeutics
Travel, Accommodations, Expenses - Pfizer
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; crispr therapeutics; Janssen Biotech; Jounce Therapeutics; Pfizer; Seagen; Symphogen
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Omar Alhalabi
No Relationships to Disclose
 
Kanishka Sircar
No Relationships to Disclose
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Ipsen; Lilly; Merck Sharp & Dohme; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Ipsen; Lilly; Lilly; Merck Sharp & Dohme; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Research Funding - Arrowhead Pharmaceuticals; Bristol-Myers Squibb; Calithera Biosciences; Eisai; Epizyme; Exelixis; Lilly; Mirati Therapeutics; Nektar; Pfizer; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Ipsen; Lilly; Nektar; Pfizer; Surface Oncology
 
Pavlos Msaouel
Honoraria - Bristol-Myers Squibb/Medarex; Exelixis; Mirati Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)